Back to top

BMY’s IZABRIGHT-Lung02 Trial Targets Growth in EGFR Lung Cancer

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) is launching a Phase III lu...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Bristol Myers Squibb Company (BMY)